GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ixekizumab   Click here for help

GtoPdb Ligand ID: 7541

Synonyms: LY-2439821 | LY2439821 | Taltz®
Approved drug Immunopharmacology Ligand
ixekizumab is an approved drug (FDA & EMA (2016))
Compound class: Antibody
Comment: Ixekizumab binds to IL-17A and blocks its action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A protein BLAST search using the variable region of the heavy chain of ixekizumab identifies this as sequence 118 from patent US7838638 [1]. In this patent binding affinity data for human IL-17 is provided for several antibody clones, but it does not specify which was chosen as ixekizumab, although mAbs 126, 121 and 104 did undergo additional experimental investigations.
Immunopharmacology Comments
Ixekizumab is an effective treatment option for psoriasis [3-4], with potential for patients with an inadequate response to anti-TNF therapies [2].
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriatic arthritis Disease Ontology: DOID:9008
 Phase 3 clinical candidate for PsA (see NCT02349295). 10
Psoriasis Disease Ontology: DOID:8893
 Approved therapeutic for psoriasis and plaque psoriasis.